Innate Pharma (IPHA) Stock Statistics & Valuation Metrics

Innate Pharma has a market cap or net worth of $192.93M. The enterprise value is $108.74M.

Innate Pharma has 92,183,525 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma’s return on equity (ROE) is -5.60 and return on invested capital (ROIC) is -59.43%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Innate Pharma had revenue of 12.62M and earned -49.47M in profits. Earnings per share was -0.61.

In the last 12 months, operating cash flow was -6.90M and capital expenditures -391.00K, giving a free cash flow of -7.29M billion.

Innate Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma upcoming earnings date is Sep 17, 2025, Before Open (Confirmed).

Innate Pharma as a current ratio of 2.60, with Debt / Equity ratio of 350.86%

In the past 12 months, Innate Pharma has paid 0.00 in taxes.

Innate Pharma EV to EBITDA ratio is -2.32, with an EV/FCF ratio of -14.91.

Innate Pharma has $80.77M in cash and marketable securities with €31.00M in debt, giving a net cash position of -$49.77M billion.

Gross margin is -100.34%, with operating margin of -408.64%, and net profit margin of -391.97%.

The average price target for Innate Pharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy